

## **LDH IB 22-28 COVID-19 commercially purchased Bebtelovimab reimbursement**

Commercial distribution of the COVID-19 treatment medication Bebtelovimab (Q0222) began on August 15, 2022. This is in addition to stock of this medication providers may have that was supplied by the federal government at no cost.

**Effective for dates of service on or after August 15, 2022, Louisiana Medicaid will require modifier *UC* to identify that the COVID-19 medication administered was commercially purchased. Providers are to use the same administration codes for both the purchased product and the medication supplied by the federal government.**

There are no changes for submitting claims related to the government-supplied medication. If the federal government provided the medication, then no modifier is to be appended and reimbursement is \$0. Seeking reimbursement for the government-provided medication is subject to review, recoupment, and further sanctions.

The COVID-19 Vaccine and Treatment fee schedule has been revised to reflect this update. The fee schedule is available on the Medicaid website: [https://www.lamedicaid.com/Provweb1/fee\\_schedules/COVID-19\\_Fee.htm](https://www.lamedicaid.com/Provweb1/fee_schedules/COVID-19_Fee.htm)

### **What is the impact of this change?**

Healthy Blue is updating our procedure file to revise the appropriate reimbursement rate and effective date for this change by October 7, 2022. We will recycle any claims that were not paid in accordance with this update by October 22, 2022.

### **What if I need assistance?**

For questions related to this information as it pertains to fee-for-service Medicaid claims processing, please contact Gainwell Technologies Provider Services at **800-473-2783** or **225-924-5040**.

If you have questions about this communication or need assistance with any other item, contact your local Provider Relations representative or call Provider Services at **844-521-6942**.